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Background: Exercise has a beta cell preserving effect in patients with type 2 diabetes. This benefit of exercise has
not been examined in type 1 diabetes. Significant beta cell function is present at the time of diagnosis of type 1
diabetes and therefore studies of beta cell preservation are ideally conducted immediately after diagnosis.
Many of the variables required to design and power such a study are currently unknown. The aim of EXTOD is to
obtain the information required to design a formal study of exercise and beta cell preservation in newly diagnosed
patients with type 1 diabetes.
Methods: Barriers to exercise will initially be assessed in a qualitative study of newly diagnosed patients. Then, sixty
newly diagnosed adult type 1 diabetes patients will be randomized to either conventional treatment or exercise,
stratified on beta cell function and fitness. The exercise group will be encouraged to increase their level of activity
to a minimum of 150 minutes of moderate to vigorous intensity exercise per week, aiming for 240 minutes per
week of exercise for 12 months. Beta cell function will be measured by meal-stimulated C peptide. Primary
outcomes are recruitment, adherence to exercise, loss to follow-up, and exercise levels in the non-intervention arm
(contamination). The secondary outcome of the study is rate of loss of beta cell function.
Discussion: The outcomes of the EXTOD study will help define the barriers, uptake and benefits of exercise in
adults newly diagnosed with type 1 diabetes. This information will enable design of a formal study to assess the
effect of exercise on beta cell preservation in newly diagnosed patients with type 1 diabetes.
Trial registration: Current controlled trials ISRCTN91388505
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The natural history of beta cell loss in type 1 diabetes
Type 1 diabetes (T1DM) is a chronic inflammatory auto-
immune disease characterized by destruction of insulin
producing beta cells and by subsequent insulin deficiency
[1]. It affects 0.3% of the UK population, approximately* Correspondence: p.narendran@bham.ac.uk
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reproduction in any medium, provided the or250,000 people, and its incidence is rising [2]. In the UK,
it has been reported to result in a shortening of life
expectancy by over 20 years [3].
The loss of beta cells that results in T1DM is a gradual
process, and between 50 and 25% of beta cell function
can be present at the time of diagnosis [4]. However this
residual function is insufficient to generate the insulin
required for metabolic control, and the lack of insulin
results in a number of metabolic derangements which if
untreated results in death. Patients with T1DM therefore
start insulin injection replacement therapy at diagnosis.
It has generally been assumed that the remaining betatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnosis. However, recent studies indicate that these
cells can persist for over 50 years following diagnosis
[5-7], and that their presence is associated with import-
ant clinical benefits. These benefits include improved
glucose control, reduced retinopathy and nephropathy,
and with more than a halving of rates of hypoglycemia
[8-11]. These benefits of preservation of beta cell function
are significant, and the FDA (USA), and EMEA (Europe)
state that even partial preservation of beta cell function
((estimated by a stimulated C peptide > 200 pmol/L -
elaborated below)) is a sufficient basis for the licensing of
new therapies for T1DM [12].
What are the benefits of beta cell preservation in people
with type 1 diabetes?
Whilst beta cell mass cannot be directly measured, it
can be accurately estimated through measurement of
stimulated C peptide (a component of the pre-insulin
molecule) following a physiological meal stimulus [13].
Meal-stimulated C peptide provides an acceptably accur-
ate estimate of beta cell function for use in studies of
beta cell preservation [14]. A meal-stimulated C peptide
value of greater than 200 pmol/L is associated with the
clinical benefits outlined above. C peptide assay technol-
ogy has improved over the recent years, and through
National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) sponsored standardization workshops,
levels of 30 pmol/L can now be measured reliably and
reproducibly across different laboratories [15]. More re-
cently, the development of sensitive assays has allowed C
peptide detection down to levels of 1.5 pmol/L [16]. Such
assays have provided even stronger support for the persis-
tence of beta cell function in people with long standing
T1DM, albeit at levels that do not provide independence
from insulin injections [17]. Current estimates therefore
are that 60% of subjects will have a stimulated C peptide
greater than 200 pmol/L at two years following diagnosis,
but that C peptide is detectable at lower levels in 64% of
people at 50 years after diagnosis [7].
How can we preserve beta cell function in people with
type 1 diabetes?
A number of medicinal products are currently under
investigation for the preservation of beta cell function in
subjects newly diagnosed with T1DM. They are largely
immunomodulatory agents that act by ‘suppressing’ the
inflammatory autoimmune process targeting the beta cell.
Whilst some of them act to modulate the autoimmune
process specifically against beta cell antigens [18], others
act through broad, non-antigen specific immune suppres-
sion [19]. Many of these therapies are associated with
significant risk of side effects. These include infection or
reactivation of latent infection, inflammation at the sitesof injection, and the risk of cancer and infection associated
with immunosuppressive therapy [20]. Furthermore, these
new therapies have yet to demonstrate significant and
sustained benefit. Whilst we clearly need to continue
investigating such novel therapies, there is also a pressing
need to examine new therapies with an acceptable side
effect profile, and which potentially could be used as an
adjunct to the medicinal products under investigation. We
are interested in the role of exercise in this regard.
Can exercise preserve beta cell function in people with
type 1 diabetes?
Exercise has been demonstrated to preserve beta cells in
animal studies [21-23]. Pancreatic sections from a rat
model of insulin deficient diabetes revealed a 33% increase
in staining for beta cells, and a 31% increase in beta cell
mass following an eight-week exercise program. The
mechanisms underlying this effect remain unclear but a
significant decease in beta cell apoptosis was reported
[24]. Exercise has a recognized anti-inflammatory effect
[25] that may therefore modulate the autoimmune process
against the islet.
These beneficial effects of exercise on beta cell function
have also been demonstrated in healthy human subjects
[26], and in the context of people with pre- or established
type 2 diabetes [27,28]. Here also, the exercise has been
of vigorous intensity with a VO2max of 70%, and of
sustained duration. The disposition index used in this
study as an estimate of beta cell function, revealed a 27%
improvement following a one-week program of exercise in
older people with impaired glucose tolerance [27]. More
recently, an eight-month exercise program in middle-aged
overweight people revealed a 60% improvement in beta
cell function and a 20% improvement in insulin resistance
with moderate intensity exercise (walking at a slow pace
for 60 minutes on three days per week) [29].
Until recently, many observers have remained skeptical
that increases in exercise can be maintained long enough
to have any significant impact on diabetes risk or help im-
prove diabetes management. However, large intervention
studies targeting subjects with impaired glucose tolerance
have demonstrated that a program of lifestyle changes
focusing on improved diet and increased exercise is able
to delay or possibly prevent the development of type 2
diabetes mellitus (T2DM) over a period of four years
[30,31]. Both studies found lifestyle intervention to result in
a 58% reduction in the incidence of diabetes, irrespective of
age. Importantly, both studies also showed that it was pos-
sible to maintain increased levels of exercise for four years.
Furthermore, we ourselves have shown that a program of
lifestyle changes focusing on improved diet and increased
exercise, reduces insulin resistance, weight, and drug usage
and improves diabetes control in newly diagnosed type 2
patients [32]. In this study, we demonstrated that with a
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sive exercise regime we can maintain increased levels of
exercise for 12 months.
We therefore believe that regular exercise, if demon-
strated to show benefit in patients with residual beta cell
function, can be undertaken and maintained by patients
with diabetes.
Hypothesis
Our hypothesis is that exercise preserves beta cell func-
tion in people with T1DM. We base this hypothesis on
previous studies of exercise in T2DM, pre-T2DM, and
people without diabetes, where exercise is associated
with preservation of beta cell function.
Research goals
In order to test our hypothesis, we will initially under-
take a qualitative study to identify barriers to the uptake
and adherence to an intensive exercise program, and
determine the most acceptable way to monitor exercise
levels. We will then undertake a pilot RCT involving an
exercise intervention in patients with recent onset T1DM
in order to:
1) Determine the proportion and characteristics of
patients with T1DM who would be willing to
take part in an RCT of exercise (that is,
recruitment rate).
2) Define the rates of exercise adherence to the
intervention and participant drop-out. The
unsupervised exercise program will aim to
encourage patients to safely increase and maintain
their exercise level to at least 150 minutes per
week, and aiming for 240 minutes per week of
vigorous intensity exercise. A minimum level of
150 minutes per week is recommended by major
diabetes organizations [33,34]. However, to
maximize the chances of seeing a benefit in beta
cell function, patients will be encouraged to aim
for 240 minutes per week.
3) Determine the rate of exercise uptake in the non-
intervention arm (that is, intervention
contamination). This issue is important because it
has the potential to dilute trial effects, and
adjustments for this will need to be made when
calculating the sample size for a definitive trial.
4) Determine the rate of loss of beta cell function
(potential effect size) in the intervention and control
arm to enable the statistical power calculations for
the subsequent definitive trial to be refined.
5) Determine (as a secondary outcome) whether the
12 months exercise intervention results in a
significant preservation of beta cell function.Methods and design
Setting and recruitment
The study will take place across 19 NHS hospital Trusts
in the UK: University Hospital Birmingham, Taunton and
Somerset, University Hospitals Bristol, North Bristol,
Gloucester Hospitals, Yeovil District Hospitals, East and
North Hertfordshire, Mid Yorkshire Hospitals, Oxford
University Hospitals, Worcestershire Acute Hospitals,
George Eliot Hospital, The Dudley Group, Walsall
Healthcare, The Royal Wolverhampton Hospitals, Heart
of England, Sandwell and West Birmingham, Weston
Area Health, Royal United Hospital Bath and Royal
Devon and Exeter Hospital. Recruitment will focus on
NHS hospital trusts as the vast majority of patients
newly diagnosed with T1DM are referred to hospital for
initiation of insulin.
Participant selection
Clinical staff at participating hospitals will identify patients
newly diagnosed with T1DM. They will approach these
patients about the study and ask permission for their con-
tact details to be forwarded to the EXTOD study team.
Interested participants will then be contacted by the study
team by telephone and invited to attend their local study
centre for a screening visit. At the first visit written in-
formed consent will be obtained by a member of the study
team (physician or research nurse). Patients will be con-
sidered eligible for enrollment in this trial if they fulfill all
the inclusion criteria and none of the exclusion criteria
(see Table 1).
Study design
The EXTOD study is designed in two phases. Phase 1 is a
qualitative study designed to inform on the most feasible
and patient-friendly way of motivating patients newly di-
agnosed with T1DM to undertake and maintain a graded
exercise program, and to determine the most acceptable
way to monitor exercise levels. This understanding is
essential for the conduct of phase 2.
Phase 2 is a pilot RCT to assess uptake, intervention
adherence, drop-out rates, and rate of uptake in the usual
care group during a 12 month exercise intervention, and
the effect of this intervention on beta cell function.
Phase 1 - qualitative study
Patients will be interviewed once face-to-face by a quali-
tative researcher. The interview format will be flexible to
allow for logistics of the large area being covered by the
study and interviews will take place either on an indivi-
dual basis or with two or more patients together as
appropriate. Interviews will be semi-structured to ensure
that key themes are covered, whilst giving participants
the opportunity to freely express their views.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Aged 16 to 60
Diagnosed with T1DM within the previous 12 weeks
Able and safe to exercise (as determined by the lead physician)
Willing to self-monitor and record blood glucose levels
Willing to take insulin as part of a multiple dose injection regime
Feel able to increase their current levels of exercise
Have a meal-stimulated C peptide value greater than 200 pmol/l (these criteria are not required
for recruitment into phase 1)
Exclusion criteria Psychological or physical disease that prevents exercise
Concomitant therapy that affects heart rate (for example, beta blocker, calcium channel antagonist) as we would
be unable to monitor their exercise adherence
Major surgery or other planned event that would prevent exercise for more than six weeks
Pregnancy or planning pregnancy
Uncontrolled blood pressure (greater than 180/100 mmHg), as it is unsafe to exercise with this blood pressure
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experience of type 1 diabetes, and what information they
were given about exercise at diagnosis (Table 2). All in-
terviews will be recorded, and interviewing will continue
until saturation is reached.Analysis
Data collection and analysis will be iterative to allow ear-
lier data to shape later data collection. The transcribed
data will be analyzed using constant comparative analysis
to identify the emerging themes which comprise inter-
viewees’ views regarding particular issues [35]. Themes
from participants of different ages and gender will be
compared and differences and similarities noted. Manage-
ment of data for analysis will be assisted by the software
package NVivo (QSR International, Victoria, Australia).
Themes and a coding frame will be developed by reading
and re-reading of the interview transcripts and through
discussions between members of the multi-disciplinary
research team.
Information from this phase will be used to refine the
intervention developed for phase 2.Phase 2 - RCT
Pre-randomization visits
Patients will be initially screened on the telephone and
potentially eligible individuals invited to attend a face-to
-face assessment to confirm eligibility (visit 1). Here the
study team will obtain informed consent, record their
clinical history and conduct a physical examination.
Participants will return in a fasting state to undertake
baseline tests including the meal-stimulated C peptide
measurement (visit 2, Table 3). Participants will return
again to undertake Astrand-Rhyming and YMCA/ACSM
cycle tests to assess fitness [36] (visit 3). Two cycle tests
will be performed to ensure that we can get an accurateestimation of fitness. A study doctor will see all patients
at visit 1.
Randomization
Randomization will be done according to computer-
generated allocation. Patients will be assigned, in a 1:1
ratio, to ‘usual care’ or ‘exercise intervention’. Alloca-
tions will remain concealed by the trial coordinator until
the patients attends visit 4 when they will be randomized
using on-line software. Randomization will be minimized
by center, meal-stimulated 90-minute C peptide, and
fitness. Due to the nature of the intervention, blinding of
the study team to the randomization arm is not possible.
Post-randomization visits
In agreement with the local GPs and hospital doctors, the
study team will undertake the ongoing diabetes manage-
ment of all trial participants for the period of the trial.
This is to ensure that similar guidelines for treatment
intervention are maintained across all sites. Patients will
be seen at baseline, 6 and 12 months by a doctor and any
changes in treatment will be made according to strict
guidelines, thus ensuring no bias between the two groups.
All participants will have eight visits. Those patients
randomized to the exercise arm will have a further five
telephone consultations (see Table 4).
Usual care
Usual care will consist of standard dietary and exercise
advice after randomization, and at the end of the study.
There will also be reviews by a study doctor and nurse
at baseline and at 6 and 12 months. At randomization,
the dietitian will meet with the patients for 45 minutes
to provide education on food intake as well as providing
information on insulin and carbohydrate dose adjust-
ment around exercise and hypoglycemia management.
Table 2 Topic guide for Phase 1 interviews
1) Moderator’s introduction
2) About the group
3) Activity and exercise behavior What exercise do you do?
What does the word ‘exercise’ mean to you? (focus on activity levels)
Why should someone exercise?
How active are you on a day to day basis/how do you feel about the amount of exercise you do?
Do you think you do enough exercise to keep healthy?
Is exercise important in the management of diabetes?
What are the recommended guidelines?
The DOH recommends 150 minutes exercise per week, what do you think of this?
Do you think this is achievable?
How do you relate to the recommended levels?
4) Barriers to exercise What are the mains reasons for not meeting the guidelines?
How do you try to overcome these barriers? How can you resolve them?
If you have a fear of having a hypo, do you make any adjustments?
If you had a magic wand what would be the one thing you could overcome in order to allow
you to do more exercise?
Has the diagnosis of diabetes changed your attitudes towards exercise?
Does education and understanding have a role in the management of your diabetes and therefore
your exercise levels?
5) Encouragement and facilitation of exercise Can you think of any ways of improving your activity levels?
How can small changes be incorporated into your lifestyle?
Are there any major themes that would help encourage people to be more active?
Would more advice or information help?
If you had to choose one intervention that would help your activity levels - which would it be?
Has anyone any successful experiences of exercising?
We are thinking about doing a study - if you were to take part how would you like to be monitored /
encouraged?
One-to-one advice from a health and fitness advisor
Attending an exercise group organized by the hospital or your GP
Support - someone who keeps in touch to see how you are doing with your exercise program
Goal setting/modification/action planning
Heart rate monitoring
Chat room with other people from the study to share ideas
Uploading BMI/weight loss onto website - self monitoring
If phone calls weren’t appropriate, what else could we do to motivate you?
6) Summary of session Outlining main points of discussion and key issues raised
Questions and thank everyone for their input
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dardized staged protocol (see disease management).
Exercise intervention
Participants allocated this arm will receive dietary advice
at baseline as for the usual care arm. Thereafter they will
be seen by a physician at 6 and 12 months and will have
nurse contact at 2, 4, 8, 12, 16, 20, 30, 36, and 42 weeks.
Again, any changes to medication will be made using a
standardized staged protocol (see Medical management).Using goal-oriented motivational interviewing tech-
niques, the aim of the physical activity intervention will
be to encourage patients to safely increase and maintain
their exercise level to at least 150 minutes per week, and
aiming for 240 minutes per week of vigorous intensity
exercise per week. This goal will be applied to all partici-
pants, regardless of their initial level of physical activity.
The activity goal will be achieved gradually over 12
weeks in a step-wise fashion and then maintained for
the remainder of the study (see Table 5). During the first
Table 3 Tests/action/questionnaires conducted at baseline, 6 and 12 months
Clinical examination Cardiovascular/respiratory/gastrointestinal/nervous system/feet
Blood pressure and heart rate
Height, weight, waist circumference
Body-fat content (bio-impedance)
Non-fasting blood collection GAD, IA-2 and zinc transporter autoantibodies
Full blood count/thyroid function
Liver/renal function
DNA (optional, only at visit 1)
Fasting blood collection Cholesterol, LDL, HDL, triglycerides
Serum/plasma storage
Inflammation markers Adiponectin, leptin, IL-6, IL-10, CRP
Meal-stimulated C peptide Participant attends fasting and drinks Fortisip 240 ml. Venous blood samples collected at time -10, 0, 15, 30, 60,
90, 120 minutes
Questionnaires International physical activity questionnaire (IPAQ)
Bandura exercise self-efficacy questionnaire
Social support for physical activity scale
Outcome expectations for exercise
Deci and Ryan motivational questions TSRQ
Health care climate questionnaire HCCQ
Pittsburgh sleep quality index (PSQI)
WHO quality of life-BREF
Fear of hypoglycemia survey
BRIEF illness perception
Problem areas in diabetes (PAID)
CES-D
Toole and Glasgow dietary questionnaire
EQ-5D
Activity monitor Small electronic device worn during waking hours for seven days. Measures physical activity by continually
monitoring and recording movements of the body
Fitness test Estimation of VO2max by submaximal test
Nurse visit Education on carbohydrate counting and insulin dose adjustment around exercise
Review of exercise diaries
Hypoglycemia management
Motivational support
Focus group for feedback Obtain feedback on the study
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something active on three to four days per week. This
will be based outside the hospital setting and monitored
as outlined below. On subsequent weeks, the activity
level will be increased to 85, 100, 110, 115, 130 and
finally 150 minutes per week. The intensity level will also
gradually increase until the patient is performing at an
intensity of 75% of their estimated maximum oxygen up-
take. If participants do not achieve the physical activity
goal within 12 weeks, they will be encouraged to achieve
it as soon as possible thereafter. Participants will be en-
couraged and supported to achieve this goal, and will be
instructed that they may accumulate activity throughouteach day in bouts of at least 10 minutes. Participants
who are active sporadically (for example, seasonally) will
be encouraged to achieve the goal consistently through-
out every month of the study.
All participants will be instructed to monitor their
physical activity on a daily basis throughout the study
using a wrist-worn heart rate monitor (Polar, Warwick,
England) and physical activity log. The heart rate moni-
tor will be worn whilst conducting exercise and will
record the length of exercise and the heart rate during
exercise. Participants will be requested to keep a daily
log of activity and their blood glucose (BG). Participants
will be asked to return the completed activity and BG
Table 4 Visit overview
Pre-
randomization
Randomization Post-randomization
Test/action Visit
1
Visit
2
Visit
3
Visit 4
(wk 0)
Visit 5
(wk 2)
Visit 6
(wk 4)
Visit 7
(wk 8)
Visit 8
(wk 12)
Visit 9
(wk 16)
Visit 10
(wk 20)
Visit 11
(wk 24)
Visit 12
(wk 24)
Visit 13
(wk 30)
Visit 14
(wk 36)
Visit 15
(wk 42)
Visit 16
(wk 48)
Visit 17
(wk 48)
Visit 18
(wk 50)
Clinical exam x x x x x
Questionnaires x x x x
Activity monitor x x x x x
Non-fasting
blood tests
x x x
Fasting blood
tests
x x x
HbA1c x x x x x
Inflammatory
markers
x x x
Urine albumin/
creatinine ratio
x x x
Meal-stimulated
C peptide
x x x
Fitness test x x x
Nurse visit x Xa x x Xa x Xa x Xa Xa
Focus group
feedback
x
X: visit attended; wk: week. avisit for exercise intervention arm only.
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Table 5 Graded exercise protocol
Week Total minutes per week Intensity (% VO2max) Heart rate target (bpm)* RPE Borg scale
1 75 55
(220-age × intensity %)a
2 85 60 Light exercise
3 and 4 100 60
5 and 6 110 65
7 115 70 Moderate exercise
8 and 9 115 70
10 and 11 130 75 Heavy breathing / sweating
12 onwards 150 (minimum) 75
This exercise program is designed to encourage a gradual increase in physical activity over the course of 12 weeks. The starting point on the scale depends on
the individual’s current fitness level.
From 12 weeks onwards, the aim is to achieve a minimum of 150 minutes per week of vigorous-intensity exercise.
RPE Borg Scale: Ratings of Perceived Exertion on a scale of 6 to 20; Heart rate in bpm (beats per minute*), afor example, a 45 year-old man wishing to undertake
exercise at 65% intensity would aim for a heart rate of (220 to 245) × 0.65 = 114 bpm [37].
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the subsequent discussion, and help monitor and en-
courage an increase in activity levels.
Use of the diary and heart rate monitor will be taught
in the first meetings with the research nurse after
randomization. Participants will negotiate appropriate
targets with the nurse based initially on baseline values
and subsequently on achievement. The setting of nego-
tiated, realistic, achievable targets, and self-monitoring
of progress towards these targets, is a key strategy for
developing confidence to exercise (self-efficacy) and is a
strategy adopted by many regular exercisers. All self-
monitoring records will be reviewed by the research
nurse. The activity log will be copied and returned to
the participant, with written or verbal comments from
the research nurse. The comments will highlight exam-
ples of positive changes the participant has made and
help the participant address any barriers to physical ac-
tivity encountered.
Participants who have not reached the activity goal of
an extra 150 minutes per week of moderate to vigorous
physical activity within four months of randomization
will be offered further help to reach this target. An
appointment will be made with a personal fitness in-
structor to examine alternative ways of helping them in-
crease their activity. They will also be offered discounted
membership at their local leisure center, where they will
have access to gym and pool facilities and numerous
supervised exercise classes (done through the exercise
prescription). However, our previous experience indi-
cates that such additional interventions are likely to be
required in only a minority of cases.Medical management
Management of T1DM, blood pressure, and lipid profile
will be undertaken by the study team for the duration of
the study. Any changes in treatment of these featureswill be made according to NICE guidelines [38] to keep
the risk of performance bias to a minimum.
Glycemic control influences beta cell function, there-
fore our aim will be to achieve optimal glycemia in both
arms of the study. To help with this, all patients will be
managed either on insulin pump therapy or on a mul-
tiple dose insulin injection regime (fast acting or soluble
insulin with each meal and background insulin at night).
At each visit, the research nurse will review the patients
blood glucose and make changes to insulin dosages if
need be, and advice will be given about how to alter
carbohydrate intake and insulin dosages to minimize
hypoglycemic episodes with exercise and obtain ideal
glucose control before, during and after exercise.
The overall aim will be to maintain the following targets:
HbA1c concentration lower than 6.5%, blood pressure
lower than 140/80 mmHg, total cholesterol concentration
lower than 4·0 mmol/L, HDL cholesterol concentration
higher than 1·0 mmol/L, LDL cholesterol concentration
lower than 2·0 mmol/L, and concentration of triglycerides
lower than 2·0 mmol/L.Assessment
Information will be collected on the number of patients
diagnosed with T1DM, who have been approached and
the reasons for not coming into the study, so that a full
consort diagram can be generated (see Figure 1).
Participants will be assessed at baseline, 6 and 12
months. A schedule and details of assessments that will
be carried out are given in Tables 3 and 4.
The clinical examination, and assessment of HbA1c,
lipids, and renal and thyroid function constitute part of
good clinical care and will inform the clinical manage-
ment of the patient.
Downloads from the heart rate monitor and review of
the exercise diaries will confirm and quantify the exercise
being undertaken by patients in the exercise arm. Data
Assessed for eligibility (n=  )
Excluded  (n=   )
Not meeting inclusion criteria (n=  )
Declined to participate (n=  )
Other reasons (n=  )
Analysed  (n=  )
Excluded from analysis (give reasons) (n=  )
Lost to follow-up (give reasons) (n=  )
Discontinued study (give reasons) (n=  )
Allocated to usual care (n=  )
Received allocated intervention (n=  )
Did not receive allocated intervention (give 
reasons) (n=  )
Lost to follow-up (give reasons) (n=  )
Discontinued study (give reasons) (n=  )
Allocated to exercise + usual care (n=  )
Received allocated intervention (n=  )
Did not receive allocated intervention (give 
reasons) (n=  )
Analysed  (n=  )
Excluded from analysis (give reasons) (n=  )
Allocation
Analysis
Follow-Up
Randomized (n=  )
Enrollment
Figure 1 Consort diagram describing flow of patients through study.
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whether we have managed to increase activity in both
arms of the study.
Changes across the study in the C peptide response to
a mixed meal will enable us to determine the effect that
exercise has on beta cell protection.
Measurement of inflammatory markers will inform
on the antiinflammatory effect of exercise. Measure-
ment of islet antibodies will allow confirmation and
sub-classification of T1DM for the final analysis of
the data.
Safety
Written advice on carbohydrate and insulin dose adjust-
ment around exercise will be prepared and distributed
to both health care professionals and patients. The study
team will keep in contact with subjects as they start and
increase their exercise participation so that the risks of
hypoglycemia and injury can be minimized. Any such
events will be documented and reviewed at the study
meetings.
Planned sample size and analyses
A minimum of 30 patients per arm is considered sufficient
to provide meaningful data to be obtained from this pilotstudy, but this will be reconsidered in the light of informa-
tion gathered in phase 1. An initial recruitment rate of
30% is anticipated followed by a 90% adherence rate to the
exercise schedule and a 15% drop-out rate. In order to
complete the pilot study with a minimum of 30 patients,
this means that 30/(0.85 × 0.9 × 0.3) = 130 patients will
need to be approached initially.
With the varying sample sizes described above, esti-
mates and 95% confidence intervals on recruitment rate,
exercise adherence rate and drop-out rate will be:
Recruitment rate 30% (22% to 39%)
Adherence rate 90% (76% to 97%)
Drop-out rate 15% (5% to 30%)
Summary statistics (mean, standard deviation (SD),
median, interquartile range (IQR), proportions) of demo-
graphic and primary outcome variables will be presented
separately for intervention and control patients. Also,
separately for intervention and control patients, change
from baseline to 12 months in fitness related variables
listed in Tables 3 and 4 will be estimated together with
95% confidence intervals. Trends over time in fitness
related variables will be illustrated graphically. Variability
in these changes will also be estimated in order to be
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trial. Comparison between intervention and control pa-
tients in change from baseline in fitness related variables
will be made giving effect size estimates for the definitive
trial. Association between fitness and demographic va-
riables will be examined at a preliminary level using
correlation analysis and chi-squared. A generalized linear
model (GLM) will be used to get an initial impression of
significance of differences between intervention and
control groups in fitness related variables. Demographic
variables and baseline fitness variable levels will be
included as covariates. Further analysis will use non-
linear mixed model analysis for outcome related fitness
variables measures including the 19 sites as a random
effect. Variation from site to site will then be used to
further assist in the design of the definitive trial. The
effect of demographic variables will also be investigated
with mixed effect modeling.
Ethics
The study has received approval from the Birmingham
East, North and Solihull Research Ethics Committee, UK
and local NHS Research and Development review panels.
The study will conform to The International Conference
on Harmonization of good clinical practice (GCP) guide-
lines as well as with the Declaration of Helsinki. A steering
committee has been established to monitor the trial.
Discussion
There is increasing evidence that exercise preserves beta
cell function in individuals who are overweight, glucose
intolerant or have type 2 diabetes. It is not known whether
this is true in people with type 1 diabetes. This pilot study
aims to provide data on recruitment rates, adherence to
exercise programs, drop-out rates and rate of loss of beta
cell function in this group of patients. This information is
required to design a formal trial of exercise to preserve
beta cell function in newly diagnosed type 1 diabetes.
This study design is of a multi-center, randomized
controlled trial and is therefore particularly robust. The
length of intervention (one year) is longer than most
other studies of exercise in type 1 diabetes. The initial
qualitative interviews will provide valuable information on
the barriers to exercise in patients with type 1 diabetes in
the UK, to enable healthcare practitioners to target exer-
cise advice more effectively.
One of the limitations of the study is the small sample
size. Due to the incidence of type 1 diabetes and the age
group we are recruiting, it is not possible to recruit large
numbers of people with recently diagnosed type 1 diabetes
even from multiple centers. As this is a pilot study, one of
the primary outcome measures is recruitment rates. If this
pilot study shows that recruitment rate is poor, we will
explore recruitment from a larger number of centersnationally or internationally. A further limitation is the
unsupervised nature of the intervention. This makes as-
sessment of adherence difficult. We are using down-
loadable heart rate monitors and accelerometer data to
validate participants’ exercise diaries.
Whilst this is the first study to look at the effects of ex-
ercise on beta cell function in type 1 diabetes, studies have
examined other benefits of exercise in this condition. Ex-
ercise has been demonstrated to improve fitness, insulin
requirement, lipids, insulin resistance and well- being, and
to reduce cardiovascular disease and mortality in people
with long standing type 1 diabetes [39].
Preservation of beta cells in new or incipient type 1 dia-
betes will have benefits to the patient as well as the NHS.
For patients, it can help avoid late complications, and for
the NHS, it can help reduce the costs associated with
treating these complications. Should exercise preserve
beta cell function, it would be advantageous and straight-
forward to enable an educational/motivational program
through existing healthcare providers targeted at increas-
ing exercise levels in patients with new type 1 diabetes.
Trial status
Recruitment commenced in November 2011 and is ex-
pected to continue until July 2013. Open to recruitment.
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